High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
Weicai HuangYao LvShasha GuanHuan YanLu HanZhikuan WangQuanli HanGuanghai DaiEvelyne CostesPublished in: Journal of translational medicine (2024)
High mutations of multiple driving genes in ctDNA and their dynamic changes could effectively predict response of mPDAC to NPS chemotherapy, with promising reliable predictive performance superior to routine clinicopathologic parameters. Inspiringly, longitudinal ctDNA tracking could predict disease progression about 2 months ahead of radiologic or CA19-9 evaluations, with the potential to precisely devise individualized therapeutic strategies for mPDAC.
Keyphrases
- circulating tumor
- cell free
- circulating tumor cells
- squamous cell carcinoma
- small cell lung cancer
- genome wide
- clinical practice
- locally advanced
- copy number
- cross sectional
- radiation therapy
- dna methylation
- advanced non small cell lung cancer
- rectal cancer
- protein kinase
- tyrosine kinase
- genome wide identification
- nucleic acid